Recurrent Melanoma Completed Phase 2 Trials for Paclitaxel (DB01229)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00255762Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By SurgeryTreatment
NCT00288041Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic MelanomaTreatment